Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine Receptor Occupancy in Healthy Humans
NCT00288782Phase 4
Key facts
- Status
- Completed
- Start
- Feb 2006
- Countries
- 1
- Sponsor
- Aarhus University
- Modality
- Small Molecules
- Drugs
- mirtazapine
- Conditions
- depressive disorders
01
Overview
Phase 4, randomised, double-blind trial of mirtazapine in depressive disorders (3 arms), sponsored by Aarhus University. Primary endpoints: Binding potential in brain regions at Day 5 and Serum concentration of mirtazapine at Day 5. Started Feb 2006; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Placebo
Placebo tablet daily for 5 days
Mirtazapine 7.5 mg
7.5 mg Mirtazapine daily for 5 days
Mirtazapine 15 mg
15 mg Mirtazapine daily for 5 days
03
Who it enrols
Healthy volunteers with no chronic or mental illness, no daily drug use, and normal brain anatomy.
04
Endpoints
Primary
Binding potential in brain regions
Serum concentration of mirtazapine
Beyond the preview
Go deeper on NCT00288782.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00288782.